These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 23314671)

  • 1. Lack of Clostridium difficile infection in patients treated with rifaximin for hepatic encephalopathy: a retrospective analysis.
    Neff GW; Jones M; Jonas M; Ravinuthala R; Novick D; Kaiser TE; Kemmer N
    J Clin Gastroenterol; 2013 Feb; 47(2):188-92. PubMed ID: 23314671
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Rifaximin therapy and Clostridium difficile infection: a note of caution.
    Zullo A; Ridola L; Hassan C
    J Clin Gastroenterol; 2013 Sep; 47(8):737. PubMed ID: 23507769
    [No Abstract]   [Full Text] [Related]  

  • 3. Rifaximin: new therapeutic indication and future directions.
    Rivkin A; Gim S
    Clin Ther; 2011 Jul; 33(7):812-27. PubMed ID: 21741091
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Rifaximin treatment in hepatic encephalopathy.
    Bass NM; Mullen KD; Sanyal A; Poordad F; Neff G; Leevy CB; Sigal S; Sheikh MY; Beavers K; Frederick T; Teperman L; Hillebrand D; Huang S; Merchant K; Shaw A; Bortey E; Forbes WP
    N Engl J Med; 2010 Mar; 362(12):1071-81. PubMed ID: 20335583
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Rifaximin in the treatment of recurrent Clostridium difficile infection.
    Mattila E; Arkkila P; Mattila PS; Tarkka E; Tissari P; Anttila VJ
    Aliment Pharmacol Ther; 2013 Jan; 37(1):122-8. PubMed ID: 23095030
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Durability of rifaximin response in hepatic encephalopathy.
    Neff GW; Jones M; Broda T; Jonas M; Ravi R; Novick D; Kaiser TE; Kemmer N
    J Clin Gastroenterol; 2012 Feb; 46(2):168-71. PubMed ID: 22011586
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparative efficacies of rifaximin and vancomycin for treatment of Clostridium difficile-associated diarrhea and prevention of disease recurrence in hamsters.
    Kokkotou E; Moss AC; Michos A; Espinoza D; Cloud JW; Mustafa N; O'Brien M; Pothoulakis C; Kelly CP
    Antimicrob Agents Chemother; 2008 Mar; 52(3):1121-6. PubMed ID: 18195066
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In vivo selection of rifamycin-resistant Clostridium difficile during rifaximin therapy.
    Carman RJ; Boone JH; Grover H; Wickham KN; Chen L
    Antimicrob Agents Chemother; 2012 Nov; 56(11):6019-20. PubMed ID: 22908175
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prolonged remission from hepatic encephalopathy with rifaximin: results of a placebo crossover analysis.
    Bajaj JS; Barrett AC; Bortey E; Paterson C; Forbes WP
    Aliment Pharmacol Ther; 2015 Jan; 41(1):39-45. PubMed ID: 25339518
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Rifaximin treatment is associated with reduced risk of cirrhotic complications and prolonged overall survival in patients experiencing hepatic encephalopathy.
    Kang SH; Lee YB; Lee JH; Nam JY; Chang Y; Cho H; Yoo JJ; Cho YY; Cho EJ; Yu SJ; Kim MY; Kim YJ; Baik SK; Yoon JH
    Aliment Pharmacol Ther; 2017 Nov; 46(9):845-855. PubMed ID: 28836723
    [TBL] [Abstract][Full Text] [Related]  

  • 11. RiMINI - the influence of rifaximin on minimal hepatic encephalopathy (MHE) and on the intestinal microbiome in patients with liver cirrhosis: study protocol for a randomized controlled trial.
    Schulz C; Schütte K; Kropf S; Schmitt FC; Vasapolli R; Kliegis LM; Riegger A; Malfertheiner P
    Trials; 2016 Feb; 17(1):111. PubMed ID: 26926775
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy of rifaximin and vancomycin combination therapy in a patient with refractory Clostridium difficile-associated diarrhea.
    Berman AL
    J Clin Gastroenterol; 2007; 41(10):932-3. PubMed ID: 18090164
    [No Abstract]   [Full Text] [Related]  

  • 13. [Rifaximin for hepatic encephalopathy in children. Case report].
    Malla I; Torres Cerino V; Villa A; Cheang Y; Giacove G; Pedreira A; Silva M
    Arch Argent Pediatr; 2011 Dec; 109(6):e113-5. PubMed ID: 22231877
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Rifaximin for the treatment of hepatic encephalopathy.
    de Melo RT; Charneski L; Hilas O
    Am J Health Syst Pharm; 2008 May; 65(9):818-22. PubMed ID: 18436728
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Rifaximin, a nonabsorbed oral antibiotic, in the treatment of hepatic encephalopathy: antimicrobial activity, efficacy, and safety.
    Williams R; Bass N
    Rev Gastroenterol Disord; 2005; 5 Suppl 1():S10-8. PubMed ID: 15976747
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Rifaximin is safe and well tolerated for long-term maintenance of remission from overt hepatic encephalopathy.
    Mullen KD; Sanyal AJ; Bass NM; Poordad FF; Sheikh MY; Frederick RT; Bortey E; Forbes WP
    Clin Gastroenterol Hepatol; 2014 Aug; 12(8):1390-7.e2. PubMed ID: 24365449
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Rifaximin for the treatment of recurrent Clostridium difficile infection after liver transplantation: A case series.
    Neff G; Zacharias V; Kaiser TE; Gaddis A; Kemmer N
    Liver Transpl; 2010 Aug; 16(8):960-3. PubMed ID: 20677286
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Breakthrough Clostridium difficile Infection in Cirrhotic Patients Receiving Rifaximin.
    Reigadas E; Alcalá L; Gómez J; Marín M; Martin A; Onori R; Muñoz P; Bouza E
    Clin Infect Dis; 2018 Mar; 66(7):1086-1091. PubMed ID: 29069372
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluation of rifaximin in management of hepatic encephalopathy.
    Wahib AA; El-Deen Salem MN; Ahmed MA; El-Dessouky YM; El-Tiby DM; El-Mola K; El-Sayed AM
    J Egypt Soc Parasitol; 2014 Dec; 44(3):677-85. PubMed ID: 25643509
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Rifaximin for the treatment of hepatic encephalopathy.
    Mullen K; Prakash R
    Expert Rev Gastroenterol Hepatol; 2010 Dec; 4(6):665-77. PubMed ID: 21108586
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.